Are aflibercept biosimilars just as safe and effective as the original drug for AMD?
Aflibercept biosimilars are copycat versions of the original drug (Eylea) that work the same way. They block a protein called VEGF that causes abnormal blood vessel growth and fluid leakage in the eye. The key question is whether these cheaper alternatives work just as well and are just as safe. A large analysis of multiple studies shows they do.
What the research says
A systematic review and meta-analysis of 11 randomized controlled trials involving over 4,000 patients found no significant differences between aflibercept biosimilars and the original drug for neovascular AMD 3. Specifically, changes in best-corrected visual acuity (a measure of how well you see) were nearly identical between the groups 3. The thickness of the central retina (central subfield thickness) also improved similarly with both treatments 3. Safety was comparable too: rates of side effects, including eye inflammation and antibody development, were not significantly different 3. The FDA has approved at least one aflibercept biosimilar, Pavblu, for neovascular AMD, confirming it meets strict standards for safety and effectiveness 1. While the original drug Eylea HD is also FDA-approved 6, biosimilars offer a more affordable option without sacrificing outcomes.
What to ask your doctor
- Would an aflibercept biosimilar be a good option for my neovascular AMD?
- Are there any differences in how often I would need injections with a biosimilar compared to the original drug?
- Has the specific biosimilar you are considering been studied in patients like me?
- What are the potential cost savings with a biosimilar, and will my insurance cover it?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.